Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Ocrelizumab

Brand: Ocrevus®
NICE TA: 585
Indication: Treating primary progressive multiple sclerosis (NICE TA585)
Disease category: Endocrine system
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

1.1 Ocrelizumab is recommended, within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. It is recommended only if the company provides it according to the commercial arrangement.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA585 - Ocrelizumab for treating primary progressive multiple sclerosis

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red